ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates that activate the immune system of cancer patients to recognize and eradicate tumors. The Company’s lead product candidate, AM0010 (pegilodecakin, PEGylated Interleukin-10), has demonstrated clinical benefit as a single agent, and in combination with both chemotherapy and checkpoint inhibitor therapy, across several tumor types. The drug is currently being investigated in a Phase 3 randomized pivotal clinical trial in pancreatic cancer patients. ARMO also has a number of other immuno-oncology product candidates in various stages of pre-clinical development including: AM0001, an anti-PD-1 monoclonal antibody; AM0003, an anti-LAG-3 checkpoint inhibitor; AM0015, form of recombinant human Interleukin-15 (IL-15); and AM0012, a form of recombinant human Interleukin-12 (IL-12).
Looking for a particular ARMO BioSciences employee's phone or email?
ARMO BioSciences Questions
The ARMO BioSciences annual revenue was $7.5 million in 2026.
1 people are employed at ARMO BioSciences.
ARMO BioSciences is based in Redwood City, California.
The NAICS codes for ARMO BioSciences are [54, 54171, 541, 541711, 5417].
The SIC codes for ARMO BioSciences are [87, 873].
Related Companies
